Get the Stockscreener App
885.94
0.93%
8.15
After Hours:
884.63
-1.31
-0.15%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $885.94, with a volume of 3.08M.
It is up +0.93% in the last 24 hours and down -7.72% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$877.79
Open:
$864.52
24h Volume:
3.08M
Relative Volume:
0.99
Market Cap:
$834.26B
Revenue:
$38.92B
Net Income/Loss:
$7.34B
P/E Ratio:
163.48
EPS:
5.4193
Net Cash Flow:
$-3.63B
1W Performance:
-3.55%
1M Performance:
-7.72%
6M Performance:
+13.88%
1Y Performance:
+64.94%
1-Day Range:
$858.81
$887.43
1-Week Range:
$858.81
$939.30
52-Week Range:
$516.57
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential - Benzinga
Eli Lilly and Company (LLY) Gets Strong Buy Rating Amid Revenue Growth - Insider Monkey
This Is the Best Pharma Stock to Invest $1,000 in Right Now - The Motley Fool
Jim Cramer Reports That Eli Lilly and Company (LLY)’s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer’s Disease - Insider Monkey
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years - The Motley Fool
Eli Lilly and Co (LLY) Stock Price Down 3.16% on Sep 27 - GuruFocus.com
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030 - The Motley Fool
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever - The Motley Fool
Novo faces ‘Nokia risk’ as it fights Lilly’s homecourt advantage - Bloomberg
Alibaba, Eli Lilly lead Friday's morning market cap stock movers - Investing.com
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason - The Motley Fool
Eli Lilly and Co (LLY) DCF Valuation: Is The Stock Undervalued? - The Acquirer's Multiple
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Stock Quote & Chart - Investors | Eli Lilly and Company
Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab - Nasdaq
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO - MSN
Eli Lilly’s EBGLYSS offers long-term disease control in atopic dermatitis trial - Clinical Trials Arena
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why. - The Motley Fool
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments - Benzinga
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs - Benzinga
Eli Lilly Stock: Is LLY Stock A Buy After Snagging Approval For A New Eczema Drug? - Investor's Business Daily
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan - Yahoo Finance
DexCom Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years - Benzinga
Is Eli Lilly Stock Still A Buy Near All-Time Highs? - Barchart
Eli Lilly hires ex-APCO healthcare chief and former government health adviser - PR Week
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis - Investors | Eli Lilly and Company
Eli Lilly & Co. (LLY) reports new data showing EBGLYSS provided sustained disease control for up to three years in more than 80% of adults and adolescents - StreetInsider.com
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis - Quantisnow
MHLW approves Eli Lilly’s Kinsula to treat Alzheimer’s in Japan - Pharmaceutical Technology
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market - Yahoo Finance
Eli Lilly’s Alzheimer’s drug approved in Japan - PharmaLive
Eli Lilly’s Alzheimer’s treatment Kisunla wins approval in Japan - MarketWatch
Eli Lilly Gets Japan OK for Kisunla Alzheimer's Disease Drug - MarketWatch
Eli Lilly's Alzheimer's drug approved in Japan - Reuters
Eli Lilly's Alzheimer's drug approved in Japan - Yahoo Canada Finance
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease - Investors | Eli Lilly and Company
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? - Morningstar
Lilly seeks court ruling that could mean big money for new weight-loss drug - Inside INdiana Business
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split) - AOL
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split) - The Motley Fool
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range (NYSE:LLY) - Seeking Alpha
Little Support For Eli Lilly's High Valuation (NYSE:LLY) - Seeking Alpha
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today - The Motley Fool
Why Eli Lilly and Palo Alto Networks are both up on news from their competitors - CNBC
Eli Lilly retains buy stock rating from Deutsche Bank on study results - Investing.com
Deutsche Bank on Eli Lilly (LLY): 'CB-1 Appetite Suppression Looks Underwhelming' - StreetInsider.com
Eli Lilly request records of people who took copies of its weight-loss drug - Indianapolis Business Journal
Lilly asks people who took compounded tirzepatide for their medical records - Seeking Alpha
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | 10% Owner |
Sep 03 '24 |
Sale |
966.69 |
24,084 |
23,281,840 |
96,891,978 |
| LILLY ENDOWMENT INC | 10% Owner |
Aug 27 '24 |
Sale |
968.46 |
24,552 |
23,777,668 |
96,916,062 |
0.41%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):